ATTR Salesforce

Quote
anonymous said:
of course they reposted. they couldn’t get anyone good to post because we have no real indication, are second to market, and have terrible leadership. have you seen where our leader came from? little linkedin search real fast will show you… pfizer. secondhand leadership with a secondhand product recruiting secondhand pfizer reps only to pay them more than they are willing to pay us
Click to expand...
Wait & watch. AZ will do very well in this space. I was interviewed for a role, didn't land in. But I'll try again in future. Loved the leadership & clarity they provided me
 




























anonymous said:
Anyone internal taking the job is making a purely lateral move with all of the expectation and pressure of selling a very expensive drug under the same misguided leadership of CVRM. It'll feel like a rare disease role for 6 months, then it'll take on a primary care feel because that's all the leadership knows.

Anyone external looking at this job. You're either desperate or lied on your resume that you have rare disease experience.
Click to expand...

Good predictions. But way off on timing. It didn't event take 6 months.
 




anonymous said:
I've been in these situations before. The difference is I was asked to promote drugs in a specific speciality and was asked to sell off label in that specific speciality. Harder to catch. We had an NDA and everything for the proposed new indication but the company didntvwant to wait. The OIG doesn't care what you're planning. They care what you're doing, the harm your may or may not be causing and especially what Medicare pays for.

This is going to be blatantly obvious as a Cardiology indication is 2 to 3 years away..And how long will Pfizer, and their on label pproduct, allow you to take their off label market share away before they start making noise?

We're not talking a drug that $400 a month med. How long until the HMOs start wonder how this neuro drug ends up with all the Cardiology scripts? I'm pretty sure Pfizer won't be shy about telling that story. Its putting the cart before the horse.
Click to expand...


Very few, if any HF specialists will Rx this for ATTR-CM off label. Pfizer's drug (tafamidis) is the only approved drug in the cardiac space with a class one recommendation on the 2022 uodated ACC/AHA guidelines with a NNT of 7.5 for mortality and NNT of 4.5 for CV-related hospitalizations. Impressive primary endpoints to say the least with placebo equivalent AE's. It also drastically improves functional capacity. They are way ahead of us, so best of luck to any of you internal/external candidates. I personally am not touching this role
 




anonymous said:
I've been in these situations before. The difference is I was asked to promote drugs in a specific speciality and was asked to sell off label in that specific speciality. Harder to catch. We had an NDA and everything for the proposed new indication but the company didntvwant to wait. The OIG doesn't care what you're planning. They care what you're doing, the harm your may or may not be causing and especially what Medicare pays for.

This is going to be blatantly obvious as a Cardiology indication is 2 to 3 years away..And how long will Pfizer, and their on label pproduct, allow you to take their off label market share away before they start making noise?

We're not talking a drug that $400 a month med. How long until the HMOs start wonder how this neuro drug ends up with all the Cardiology scripts? I'm pretty sure Pfizer won't be shy about telling that story. Its putting the cart before the horse.
Click to expand...


Pfizer's drug (tafamidis) is a beast in the ATTR-CM space and now has a class 1 recommendation for cardiac amyloidosis on the updated (2022) ACC/AHA guidelines. The data, both primary and secondary endpoints are impressive and safety that's placebo equivalent. The docs hate the price but love the drug based on conversations I've had. The amyloid centers that are using tafamidis have pathways that use first line for wATTR or hATTR once the patient has been identified and approved. Good luck trying to go off label in the cardio space. It just isn't going to happen. The HF docs only use tafamidis on label, so there are no off label scripts to take.
 




anonymous said:
Pfizer's drug (tafamidis) is a beast in the ATTR-CM space and now has a class 1 recommendation for cardiac amyloidosis on the updated (2022) ACC/AHA guidelines. The data, both primary and secondary endpoints are impressive and safety that's placebo equivalent. The docs hate the price but love the drug based on conversations I've had. The amyloid centers that are using tafamidis have pathways that use first line for wATTR or hATTR once the patient has been identified and approved. Good luck trying to go off label in the cardio space. It just isn't going to happen. The HF docs only use tafamidis on label, so there are no off label scripts to take.
Click to expand...

Always the love the know it all who knows surface info but not the underbelly truth. A beast because its the only one with the indication today. The world is changing fast. The ATTR experts are waiting for better which is coming in a possible trifecta within a year. Pfizer is a shell of what it was. only thing to save them may be savvy contracting but they suck at that too. Been playing the two thousand pound gorilla routine for too long. pay back from all sides is a coming. The drug was the pioneer. Pioneers get slaughtered. Here endeth the lesson.
 




anonymous said:
Always the love the know it all who knows surface info but not the underbelly truth. A beast because its the only one with the indication today. The world is changing fast. The ATTR experts are waiting for better which is coming in a possible trifecta within a year. Pfizer is a shell of what it was. only thing to save them may be savvy contracting but they suck at that too. Been playing the two thousand pound gorilla routine for too long. pay back from all sides is a coming. The drug was the pioneer. Pioneers get slaughtered. Here endeth the lesson.
Click to expand...

Thank you for the knowledge drop, Jedi Master. What would we have done without you? No one is arguing the anticipated arrival of additional therapies in this space which ='s Great for patients. No one is arguing that Pfizer isn't a shell of its former self. We can agree on that too. The "slaughter" that you speak of is at least 1-2 years away, if it even materializes. The "better" that you are suggesting hasn't been proven clinically, and the endpoints in ongoing trials doesn't support any clinical superiority. Maybe different MOA's. If you've never spent extensive amounts of time with HF specialists, you'll quickly realize the level of apathy and how difficult it is just to get them to even think about clinical differential and diagnosis in ATTR-CM. It's a major uphill battle. The good news is, the more therapies introduced to the marketplace, the more education and ultimately the more all of these products will be used. In the meantime, leave it to those that have lived in this space for many years. Hope that helped
 




anonymous said:
Thank you for the knowledge drop, Jedi Master. What would we have done without you? No one is arguing the anticipated arrival of additional therapies in this space which ='s Great for patients. No one is arguing that Pfizer isn't a shell of its former self. We can agree on that too. The "slaughter" that you speak of is at least 1-2 years away, if it even materializes. The "better" that you are suggesting hasn't been proven clinically, and the endpoints in ongoing trials doesn't support any clinical superiority. Maybe different MOA's. If you've never spent extensive amounts of time with HF specialists, you'll quickly realize the level of apathy and how difficult it is just to get them to even think about clinical differential and diagnosis in ATTR-CM. It's a major uphill battle. The good news is, the more therapies introduced to the marketplace, the more education and ultimately the more all of these products will be used. In the meantime, leave it to those that have lived in this space for many years. Hope that helped
Click to expand...
I bet your customers just love your word salads.
 




anonymous said:
Thank you for the knowledge drop, Jedi Master. What would we have done without you? No one is arguing the anticipated arrival of additional therapies in this space which ='s Great for patients. No one is arguing that Pfizer isn't a shell of its former self. We can agree on that too. The "slaughter" that you speak of is at least 1-2 years away, if it even materializes. The "better" that you are suggesting hasn't been proven clinically, and the endpoints in ongoing trials doesn't support any clinical superiority. Maybe different MOA's. If you've never spent extensive amounts of time with HF specialists, you'll quickly realize the level of apathy and how difficult it is just to get them to even think about clinical differential and diagnosis in ATTR-CM. It's a major uphill battle. The good news is, the more therapies introduced to the marketplace, the more education and ultimately the more all of these products will be used. In the meantime, leave it to those that have lived in this space for many years. Hope that helped
Click to expand...

Sometimes people need it spelled out. I do believe we will eventually compete and the attr cm market needs options
 




























Top Bottom
Back
Quote